Figure 1 | British Journal of Cancer

Figure 1

From: A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

Figure 1

(A) Time to progression for all patients, including patients who came off study for events not related to disease progression (censored). Median time to progression was 2.5 months. (B) Time to progression for evaluable patients by tumour type and dose level. Coloured bars indicate best radiographic response (red— progressive disease, blue—stable disease, and green—confirmed partial response). *Dose level 1, **Dose level 2. (C) Waterfall plot of best radiographic response by RECIST for evaluable patients by tumour type. Coloured bars indicate best clinical outcome (red—progressive disease, blue- stable disease, and green—partial response). Note that several patients came off study for clinical progression of disease despite meeting radiologic criteria for stable disease. Dotted lines indicate criteria for progression or partial response. A full color version of this figure is available at the British Journal of Cancer online.

Back to article page